Monitoring and Outcomes

Chronic Obstructive Pulmonary Disease

Volumn , Issue , 2008, Pages 181-188

  Jones, Paul W ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Diagnostic marker; Dyspnoea scales; Health status; Impairments; Questionnaires

Indexed keywords

EID: 79960425476     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470755976.ch16     Document Type: Chapter

References (48)

1. Guyatt GH, Townsend M, Berman LB, Pugsley SO. Quality of life in patients with chronic airflow limitation. Br J Dis Chest 1987; 81: 45-54.
2. Killian KJ, Leblanc P, Martin DH et al. Exercise capacity and ventilatory, circulatory and symptom limitation in patients with chronic airflow limitation. Am Rev Respir Dis 1992; 146: 935-40.
3. Spruit MA, Gosselink R, Troosters T et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-1. Thorax 2003; 58: 752-6.
4. British Lung Foundation. Living with Chronic Obstructive Pulmonary Disease. London: British Lung Foundation, 2000.
5. Janssens JP, Rochat T, Frey JG et al. Health-related quality of life in patients under long-term oxygen therapy: a homebased descriptive study. Respir Med 1997; 91: 592-602.
6. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56: 880-7.
7. Hickey AM, Bury G, O'Boyle CA et al. A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV/AIDS. BMJ 1996; 313: 29-33.
8. Jones PW, Willits LR, Burge PS, Calverley PMA. Disease severity and the effect of fluticasone proprionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003; 21: 1-6.
9. Bestall JC, Paul EA, Garrod R et al. Usefulness of the Medical Research Council (MRC) Dyspnoea Scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-6.
10. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. Measurements of dyspnea: contents, interobserver correlates of two new clinical indices. Chest 1984; 85: 751-8.
11. Mahler DA, Donohue JF, Barbee RA et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-65.
12. Mahler DA, Wire P, Horstman D et al. Effectiveness of fluticsone proprionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084-91.
13. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure. Chest 1998; 113: 619-24.
14. Ries AL, Kaplan RM, Myers R, Prewitt LM. Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. Am J Respir Crit Care Med 2003; 167: 880-8.
15. Bergner M. The sickness impact profile. In: Walker SR, Rosser RM, eds. Quality of Life: Assessment and Application. Boston: MTP, 1987: 79-94.
16. Jones PW. Quality of life measurement for patients with diseases of the airways. Thorax 1991; 46: 676-82.
17. Lareau SC, Breslin EH, Meek PM. Functional status instruments: outcome measure in the evaluation of patients with chronic obstructive pulmonary disease. Heart Lung 1996; 25: 212-24.
18. Weaver TE, Narsavage GL, Guilfoyle MJ. The development and psychometric evaluation of the Pulmonary Functional Status Scale: an instrument to assess functional status in pulmonary disease. J Cardiopulm Rehabil 1998; 18: 105-11.
19. Okubadejo AA, O'Shea L, Jones PW, Wedzicha JA. Home assessment of activities of daily living in patients with severe chronic obstructive pulmonary disease on long-term oxygen. Eur Respir J 1997; 10: 1572-5.
20. Garrod JC, Bestall EA, Paul EA, Wedzicha JA, Jones PW. Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living Scale (LCADL). Respir Med 2000; 2000: 589-96.
21. Spencer S, Calverley PMA, Burge PS, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 122-8.
22. Jones PW, Bosh TK. Changes in quality of life in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-9.
23. Griffiths TL, Burr ML, Campbell IA et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000; 355: 362-8.
24. Man WD-C, Polkey MI, Donaldson N, Gray BJ, Moxham J. Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. BMJ 2004; 329: 1209-11.
25. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: 773-8.
26. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85(Suppl B): 25-31.
27. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure for chronic airflow limitation: the St George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-7.
28. Puhan MA, Behnke M, Laschke M et al. Self-administration and standardisation of the chronic respiratory questionnaire: a randomised trial in three German-speaking countries. Respir Med 2004; 98: 342-50.
29. Schunemann HJ, Griffith L, Jaeschke R et al. A comparison of the original chronic respiratory questionnaire with a standardized version. Chest 2003; 124: 1421-9.
30. Wedzicha JA, Bestall JC, Garrod R et al. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J 1998; 12: 363-9.
31. Maille AR, Koning CJ, Zwinderman AH et al. The development of the 'Quality-of-life for Respiratory Illness Questionnaire (QOL-RIQ)': a disease-specific quality-of-life questionnaire for patients with mild to moderate chronic non-specific lung disease. Respir Med 1997; 91: 297-309.
32. Hyland ME, Singh SJ, Sodergren SC, Morgan MP. Development of a shortened version of the Breathing Problems Questionnaire suitable for use in a pulmonary rehabilitation clinic: a purpose-specific, disease-specific questionnaire. Qual Life Res 1998; 7: 227-33.
33. Hajiro T, Nishimura K, Jones PW et al. A novel, short and simple questionnaire to measure health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1874-8.
34. Alemayehu B, Aubert RE, Feifer RA, Paul LD. Comparative analysis of two quality-of-life instruments for patients with chronic obstructive pulmonary disease. Value Health 2002; 5: 436-41.
35. Yohannes AM, Roomi J, Waters K, Connolly MJ. Quality of life in elderly patients with COPD: measurement and predictive factors. Respir Med 1998; 92: 1231-6.
36. Hajiro T, Nishimura K, Tsukino M et al. Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 785-90.
37. Domingo-Salvany A, Lamarca R, Ferrer M et al. Healthrelated quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 680-5.
38. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmnary disease. Am J Respir Crit Care Med 2003; 167: 544-9.
39. Oga T, Nishimura K, Tsukino M et al. Health status measured with the CRQ does not predict mortality in COPD. Eur Respir J 2002; 20: 1147-51.
40. Jones PW. Interpreting thresholds for a clinically significant changes in health status in asthma and COPD. Eur Respir J 2002; 19: 398-404.
41. Vincken W, van Noord JA, Greefhorst AP et al., Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002; 19: 209-16.
42. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 209-16.
43. O'Donnell DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-40.
44. Spencer S, Calverley PMA, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 1-5.
45. Oga T, Nishimura K, Tsukino M et al. Longitudinal changes in health status using the chronic respiratory disease questionnaire and pulmonary function in patients with stable chronic obstructive pulmonary disease. Qual Life Res 2004; 13: 1109-16.
46. Burge PS, Calverley PM, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303.
47. Wilson R, Allegra L, Huchon G et al., Mosaic Study Group. Short-term and long-term outcomes of moxifloxacin compared to standard antiobiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-64.
48. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589-93.